Nuclear Medicine and Biology
Volume 33, Issue 5 , Pages 677-683, July 2006

An improved method of 18F peptide labeling: hydrazone formation with HYNIC-conjugated c(RGDyK)

  • Yun-Sang Lee

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul 110-799, Korea
    • Department of Manufacturing Pharmacy, College of Pharmacy, Seoul National University, Seoul 151-742, Korea
  • ,
  • Jae Min Jeong

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Corresponding Author InformationCorresponding authors. Jae Min Jeong is to be contacted at Department of Nuclear Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Jongno-gu, Seoul 110-744, Korea. Tel.: +82 2 2072 3805; fax: +82 2 745 7690. Young-Ger Suh, Tel.: +82 2 880 7875; fax: +82 2 888 0649.
  • ,
  • Hyung Woo Kim

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul 110-799, Korea
  • ,
  • Young Soo Chang

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul 110-799, Korea
  • ,
  • Young Joo Kim

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea
  • ,
  • Mee Kyung Hong

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea
  • ,
  • Ganesha B. Rai

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
  • ,
  • Dae Yoon Chi

      Affiliations

    • Department of Chemistry, Inha University, Inchon 402-751, Korea
  • ,
  • Won Jun Kang

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
  • ,
  • Joo Hyun Kang

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea
  • ,
  • Dong Soo Lee

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
  • ,
  • June-Key Chung

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea
  • ,
  • Myung Chul Lee

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
  • ,
  • Young-Ger Suh

      Affiliations

    • Department of Manufacturing Pharmacy, College of Pharmacy, Seoul National University, Seoul 151-742, Korea
    • Corresponding Author InformationCorresponding authors. Jae Min Jeong is to be contacted at Department of Nuclear Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Jongno-gu, Seoul 110-744, Korea. Tel.: +82 2 2072 3805; fax: +82 2 745 7690. Young-Ger Suh, Tel.: +82 2 880 7875; fax: +82 2 888 0649.

Received 8 February 2006; received in revised form 7 April 2006; accepted 8 April 2006. published online 15 June 2006.

Abstract 

Radiolabeled αvβ3-integrin antagonists are increasingly investigated as a means of imaging angiogenesis. Several methods of labeling αvβ3-integrin binding peptide with 18F have been reported recently. In the present study, we devised a straightforward means for labeling Arg–Gly–Asp (RGD) peptide with 18F via hydrazone formation between c(RGDyK)-hydrazinonicotinic acid (HYNIC) (3) and 4-[18F]-fluorobenzaldehyde ([18F]4). The resulting reaction mixture was purified by HPLC to give 4′-[18F]-fluorobenzylidenehydrazone-6-nicotinamide-c(RGDyK) ([18F]5). The conjugation efficiency of 3 and 4 to form [18F]5 was 95.2%, and the radiochemical purity of [18F]5 after purification was >99%. The specific activity of [18F]5 estimated by radio-HPLC was 20.5 GBq/μmol (end of synthesis). Competitive binding assay of c(RGDyK) (1) and 5 was performed using [125I]iodo-c(RGDyK) as a radioligand, and Ki values were found to be 2.8 and 21.7 nM, respectively. For the biodistribution study, the angiogenic mouse model was established by inducing unilateral ischemia on the left hindlimbs of ICR mice after femoral artery ablation. Seven days after inducing ischemia, [18F]5 was administered to the mice through the tail vein. Ischemic muscle uptake of [18F]5 was significantly higher than that of normal muscle (P<.01). Specific uptake was confirmed by coinjection of 1 with [18F]5. Here, we successfully labeled RGD peptide with 18F via hydrazone formation between 3 and 4, resulting to [18F]5. [18F]5 was found to have high affinity for αvβ3-integrin and to accumulate specifically in ischemic hindlimb muscle of mice. We suggest that 18F labeling via formation of hydrazone between HYNIC peptide and [18F]4 is a useful method for labeling c(RGDyK), which can be applied for imaging angiogenesis.

Keywords: Peptide labeling, 18F, αvβ3-Integrin, RGD peptide, HYNIC, [18F]Fluorobenzaldehyde

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0969-8051(06)00070-9

doi:10.1016/j.nucmedbio.2006.04.004

Nuclear Medicine and Biology
Volume 33, Issue 5 , Pages 677-683, July 2006